FDA presses its campaign against rogue regenerative med players, cites StemGenex for illegal sales
The FDA’s campaign against the “bad actors” operating in regenerative medicine is far from complete.
The regulator on Tuesday admonished San Diego-based StemGenex Biologic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.